STEMCELL Technologies Ruxolitinib | B-LABO France
STEMCELL Technologies Ruxolitinib
Réf. : BL-RE-126586Réf. fabricant : 17190212 1 mg
93,15 € HT
JAK/STAT pathway inhibitor; Inhibits JAK1 and JAK2
CAS
941678-49-5
Synonyme
INCB 018424, INC 424
Quantité
1 mg
Formule moléculaire
C17H18N6
Pureté
≥98%
Marque
STEMCELL Technologies
Caractéristiques principales
Ruxolitinib is an ATP mimic that inhibits all Janus-associated kinase (JAK) family kinases with a preference for JAK-1 and JAK-2 over JAK-3 and TYK2 with IC50 values of 3.3, 2.8, 428 and 19 nM respectively (Verstovsek; Quintás-Cardama et al.)
Suppresses erythroid progenitor colony formation from peripheral blood mononuclear cells of polycythemia vera patients with the constitutively active JAK2 V617F mutation
Reduces malignant cell proliferation and decreases interleukin-6 and TNF-α signaling in a JAK2 V617F-driven mouse model of myeloproliferative disorder (Quintás-Cardama et al.)
Promotes hair regrowth in a mouse model of alopecia areata (Xing et al.)
Caractéristiques techniques
Marque
STEMCELL Technologies
Réf. B-LABO
BL-RE-126586
Réf. fabricant
17190212
CAS
941678-49-5
Synonyme
INCB 018424, INC 424
Quantité
1 mg
Formule moléculaire
C<sub>17</sub>H<sub>18</sub>N<sub>6</sub>
Pureté
≥98%
Une question, une configuration particulière ? Contactez-nous pour un devis.